Iscaffpharma and Sortina pharma enter a collaboration agreement to generate cure for cancer

Per Setterberg och Sara Rhost

With the agreement that has now been concluded between Iscaffpharma and Sortina Pharma, more effective products to cure aggressive breast cancer can be generated. Sortina Pharma, which is developing a new medical treatment, can now benefit from Iscaffpharma's unique technology. This provides a drug fingerprint predicting the effects in humans for new cancer drugs.

Previous
Previous

Clinical article: Berger et al 2021 BMC Cancer

Next
Next

Research article: Rhost et al., BCR, 2018